Loading...
XSTO
IZAFE B
Market cap8mUSD
May 28, Last price  
0.26SEK
1D
4.03%
1Q
-4.44%
Jan 2017
-96.73%
IPO
-90.44%
Name

iZafe Group AB

Chart & Performance

D1W1MN
P/E
—
P/S
10.42
EPS
—
Div Yield, %
—
Shrs. gr., 5y
66.64%
Rev. gr., 5y
-11.10%
Revenues
8m
+336.55%
3,75026,41939,1015,698000155,0007,571,00014,328,0008,904,000442,000729,0001,822,0007,954,000
Net income
-21m
L-36.26%
-5,907,245-4,941,580-2,917,935-7,228,886-3,170,867-2,596,712-6,356,026-4,269,000-11,312,000-23,116,000-12,754,000-39,277,000-23,526,000-32,174,999-20,509,000
CFO
-11m
L+0.88%
-1,621,933-941,317-829,552-1,772,786-4,316,036-3,719,000-1,410,000-15,319,000-24,567,000-33,493,000-21,457,000-11,256,000-11,355,000

Profile

iZafe Group AB (publ), a life-science company, engages in the research, development, and marketing of digital medical solutions and services for safer drug management at home. The company provides Dosell, an automated drug dispenser that handles dose bags, facilitates and enables independent medication, and reminds and alerts if the current dose is not taken at the right time. It serves consumers, and public and private-sector care providers in Sweden, the Nordic region, and internationally. The company was formerly known as MediRätt AB (publ) and changed its name to iZafe Group AB (publ) in May 2019. iZafe Group AB (publ) was incorporated in 2008 and is headquartered in Stockholm, Sweden.
URL
https://izafe.se/
IPO date
Apr 04, 2011
Employees
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
7,954
336.55%
1,822
149.93%
729
64.93%
Cost of revenue
9,588
4,656
3,506
Unusual Expense (Income)
NOPBT
(1,634)
(2,834)
(2,777)
NOPBT Margin
Operating Taxes
(3,541)
(60)
Tax Rate
NOPAT
(1,634)
707
(2,717)
Net income
(20,509)
-36.26%
(32,175)
36.76%
(23,526)
-40.10%
Dividends
Dividend yield
Proceeds from repurchase of equity
18,567
8,004
BB yield
-27.82%
-34.40%
Debt
Debt current
6,584
1,037
1,139
Long-term debt
1,084
4,011
6,382
Deferred revenue
333
Other long-term liabilities
372
(333)
Net debt
5,518
(786)
5,820
Cash flow
Cash from operating activities
(11,355)
(11,256)
(21,457)
CAPEX
(2,659)
Cash from investing activities
(1,023)
(1,457)
(2,510)
Cash from financing activities
8,694
16,846
6,942
FCF
2,638
2,664
(1,992)
Balance
Cash
2,150
5,834
1,701
Long term investments
Excess cash
1,752
5,743
1,665
Stockholders' equity
(121,139)
(105,630)
(92,816)
Invested Capital
137,451
133,879
135,698
ROIC
0.52%
ROCE
EV
Common stock shares outstanding
275,586
231,755
79,953
Price
0.21
-25.69%
0.29
-1.03%
0.29
-64.03%
Market cap
58,975
-11.64%
66,746
186.88%
23,266
-37.82%
EV
64,493
65,960
29,086
EBITDA
(1,634)
17,025
1,588
EV/EBITDA
3.87
18.32
Interest
240
182
Interest/NOPBT